Claritev Corporation Is Selected By General Dynamics Information Technology To Support CDC?s World Trade Center Health Program

Claritev Corporation was chosen by General Dynamics Information Technology (GDIT) to support the CDC's World Trade Center Health Program. Claritev will use its provider network to administer care for responders and survivors of 9/11, focusing on network development and provider access.

Original reporting
Published Sep 22, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 5:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$CTEV
Relevance
5/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Low
01

Why it matters

The award expands Claritev's service footprint but lacks disclosed financial terms, limiting immediate market impact.

02

Market read

Minimal short-term trading relevance due to lack of disclosed financial scale and private status of the company.

03

What to watch

Potential future extensions or related government contracts could enhance relevance.

Relevance 5/10Novelty 3/10Timing: announcement today

Background

Claritev Corporation, a provider of healthcare network services, was selected by General Dynamics Information Technology to support the World Trade Center Health Program.

Market effects

None significant; contract pertains to health program services.

Limited to Claritev's operating regions.

Low

Counterpoint

The contract may not materially affect Claritev's valuation given its likely private status.

Key entities

  • Claritev Corporation

    Healthcare network service provider

  • General Dynamics Information Technology

    Defense contractor facilitating the contract

Related articles

$CTEVMedAI 8/10

Claritev Q2 Earnings Call Highlights

Claritev (NYSE:CTEV) reported Q2 No Surprises Act-related revenue growth attributed mainly to one client, with management saying claim mix drove lower charges per claim. Bookings were $30M ACV in Q2 and $74M in H1, exceeding 2025 total and targeting over $100M for FY. FY revenue guidance raised to $1.00B-$1.02B and adjusted EBITDA to $610M-$620M.

$CTEVMed

Claritev Corporation Reports Second Quarter 2026 Results

Claritev Corp (CTEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. E Claritev Corporation Reports Second Quarter 2026 Results – Q2 2026 Revenues of $257.5 million grew 6.6% compared to Q2 2025 – Net Loss of $59.2 million – Adjusted EBITDA of $155.8 million increased 1.1% compared to Q2 2025 (Adjusted EBITDA Margin of 60.5% versus 63.8% in Q2 202

$CAPRHighAI 8/10

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

Capricor (CAPR) stock rose after-hours as the company reaffirmed confidence in its Deramiocel treatment ahead of a November 22 decision. The HOPE-3 trial met its primary endpoint, showing a 1.1-point improvement in upper limb function. Capricor reported a Q3 net loss of $42.7 million and $198.5 million in cash reserves. Retail sentiment on StockTwits was extremely bullish, with mixed opinions on approval odds. CAPR stock is down 69% year-to-date.